Sunday, November 10, 16:45–17:00. Georgia World Congress Center, Atlanta, USA
Presenting author: Ronald van Vollenhoven, Netherlands
What our Editorial Board said:
The SELECT-EARLY trial should provide more information regarding whether or not the JAK1 selective inhibitor upadacitinib continues to compare favorably with methotrexate as monotherapy in patients with early rheumatoid arthritis (RA). If the results are impressive, and there are no new safety signals, there will be even more intense discussion of the best choice for initial therapy in RA.